PlainRecalls
FDA Drug Moderate Class II Ongoing

Metoprolol Succinate Extended-Release Tablets, USP, 25 mg, Packaged in a) 100-count bottle, NDC 70010-780-01; b) 500-count bottle, NDC 70010-780-05; Rx only, Manufactured by: Granules India Limited, Hyderadab-500 081, India, Manufactured for: Granules Pharmaceuticals Inc., Chantilly, VA 20151,

Reported: July 9, 2025 Initiated: June 24, 2025 #D-0510-2025

Product Description

Metoprolol Succinate Extended-Release Tablets, USP, 25 mg, Packaged in a) 100-count bottle, NDC 70010-780-01; b) 500-count bottle, NDC 70010-780-05; Rx only, Manufactured by: Granules India Limited, Hyderadab-500 081, India, Manufactured for: Granules Pharmaceuticals Inc., Chantilly, VA 20151,

Reason for Recall

Failed Dissolution Specifications: Product failed to meet dissolution acceptance criteria in the stability studies at the 6th month (25¿C/60% RH) long-term.

Details

Units Affected
27,648 100-count Bottles; 5,376 500-count Bottles
Distribution
Nationwide in the USA.
Location
Chantilly, VA

Frequently Asked Questions

What product was recalled?
Metoprolol Succinate Extended-Release Tablets, USP, 25 mg, Packaged in a) 100-count bottle, NDC 70010-780-01; b) 500-count bottle, NDC 70010-780-05; Rx only, Manufactured by: Granules India Limited, Hyderadab-500 081, India, Manufactured for: Granules Pharmaceuticals Inc., Chantilly, VA 20151,. Recalled by Granules Pharmaceuticals Inc.. Units affected: 27,648 100-count Bottles; 5,376 500-count Bottles.
Why was this product recalled?
Failed Dissolution Specifications: Product failed to meet dissolution acceptance criteria in the stability studies at the 6th month (25¿C/60% RH) long-term.
Which agency issued this recall?
This recall was issued by the FDA Drug on July 9, 2025. Severity: Moderate. Recall number: D-0510-2025.